Friday, January 1, 2016

AstraZeneca is nearing another Patent Cliff

ASTRAZENECA UPCOMING PATENT EXPIRIES - CRESTOR, NEXIUM, SYMBICORT, SEROQUEL XR, PULMICORT
Over the next three years AZN will need to replace sales worth $10b with new pipeline products. In 2015, AZN is expected to generate $24b in annual sales. The sales at risk of generic competition is approximately 40 percent of its 2015 sales

at
Subscribe to: Post Comments (Atom)